About Prelude Therapeutics
Prelude Therapeutics is a company based in Philadelphia (United States) founded in 2016 by Kris Vaddi. It operates as a HealthTech. Prelude Therapeutics has raised $145 million across 4 funding rounds from investors including Fidelity Investments and Orbimed. The company has 131 employees as of December 31, 2024. Prelude Therapeutics offers products and services including SMARCA2 Degraders, KAT6A Degraders, Precision ADCs, and CDK Inhibitors. Prelude Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Philadelphia, United States
- Employees 131 as on 31 Dec, 2024
- Founders Kris Vaddi
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Prelude Therapeutics Incorporated
-
Annual Revenue
$7 M0as on Dec 31, 2024
-
Net Profit
$-127.17 M-4.38as on Dec 31, 2024
-
EBITDA
$-137.94 M-5.21as on Dec 31, 2024
-
Total Equity Funding
$145 M (USD)
in 4 rounds
-
Latest Funding Round
$50 M (USD), Series C
Aug 24, 2020
-
Investors
Fidelity Investments
& 1 more
-
Employee Count
131
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Prelude Therapeutics
Prelude Therapeutics is a publicly listed company on the NASDAQ with ticker symbol PRLD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Prelude Therapeutics
Prelude Therapeutics offers a comprehensive portfolio of products and services, including SMARCA2 Degraders, KAT6A Degraders, Precision ADCs, and CDK Inhibitors. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
SMARCA2 degraders are developed for cancer treatment efficacy.
KAT6A degraders are designed for breast cancer treatment.
Precision ADCs are created for targeted cancer therapy.
CDK inhibitors are formulated for various cancer treatments.
Unlock access to complete
Funding Insights of Prelude Therapeutics
Prelude Therapeutics has successfully raised a total of $145M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $50.0M
-
First Round
First Round
(11 Jul 2016)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2020 | Amount | Series C - Prelude Therapeutics | Valuation | Fidelity Investments | |
| Jun, 2019 | Amount | Series B - Prelude Therapeutics | Valuation | Orbimed |
|
| Aug, 2018 | Amount | Series B - Prelude Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Prelude Therapeutics
Prelude Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Prelude Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Prelude Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Prelude Therapeutics Comparisons
Competitors of Prelude Therapeutics
Prelude Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Prelude Therapeutics
Frequently Asked Questions about Prelude Therapeutics
When was Prelude Therapeutics founded?
Prelude Therapeutics was founded in 2016.
Where is Prelude Therapeutics located?
Prelude Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Who is the current CEO of Prelude Therapeutics?
Kris Vaddi is the current CEO of Prelude Therapeutics. They have also founded this company.
Is Prelude Therapeutics a funded company?
Prelude Therapeutics is a funded company, having raised a total of $145M across 4 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Jul 11, 2016.
How many employees does Prelude Therapeutics have?
As of Dec 31, 2024, the latest employee count at Prelude Therapeutics is 131.
What is the annual revenue of Prelude Therapeutics?
Annual revenue of Prelude Therapeutics is $7M as on Dec 31, 2024.
What does Prelude Therapeutics do?
Prelude Therapeutics is engaged in the discovery and development of innovative cancer medicines. The company specializes in precision oncology, targeting high unmet needs with novel drug candidates. Programs include first-in-class SMARCA2 and KAT6A degraders, alongside precision antibody-drug conjugates (ADCs). Their expertise in targeted protein degradation is leveraged to advance next-generation therapies. Collaborations with partners like AbCellera enhance their ADC development. The focus remains on extending precision medicine benefits to cancer patients across various tumor types and resistance mechanisms.
Who are the top competitors of Prelude Therapeutics?
Prelude Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
What products or services does Prelude Therapeutics offer?
Prelude Therapeutics offers SMARCA2 Degraders, KAT6A Degraders, Precision ADCs, and CDK Inhibitors.
Is Prelude Therapeutics publicly traded?
Yes, Prelude Therapeutics is publicly traded on NASDAQ under the ticker symbol PRLD.
Who are Prelude Therapeutics's investors?
Prelude Therapeutics has 2 investors. Key investors include Fidelity Investments, and Orbimed.
What is Prelude Therapeutics's ticker symbol?
The ticker symbol of Prelude Therapeutics is PRLD on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.